Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInventory AverageInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Unicycive Therapeutics (UNCY) Equity Average (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Equity Average readings, the most recent being -$10.2 million for Q4 2024.

  • On a quarterly basis, Equity Average fell 5345.07% to -$10.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$10.2 million, a 5345.07% decrease, with the full-year FY2024 number at $1.8 million, up 184.73% from a year prior.
  • Equity Average hit -$10.2 million in Q4 2024 for Unicycive Therapeutics, up from -$21.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.9 million in Q1 2022 to a low of -$21.3 million in Q3 2024.
  • Median Equity Average over the past 3 years was -$7.9 million (2023), compared with a mean of -$5.2 million.
  • The widest YoY moves for Equity Average: up 14.07% in 2024, down 5345.07% in 2024.
  • Unicycive Therapeutics' Equity Average stood at $2.1 million in 2022, then plummeted by 109.01% to -$187500.0 in 2023, then tumbled by 5345.07% to -$10.2 million in 2024.
  • The last three reported values for Equity Average were -$10.2 million (Q4 2024), -$21.3 million (Q3 2024), and -$19.7 million (Q2 2024) per Business Quant data.